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1. Introduction 
Basically, diagnosis inherited diseases in gestation is very important. But amplication of the 
progress in early stage of pregnance is the serious and great aim for rapid application of risk 
assesment for both and fetus. Fetal genetic tissues collected through techniques such as 
amniocentesis and chorionic villus sampling (CVS) for prenatal diagnosis of fetal genetic 
diseases. These procedures are associated with a risk of fetal loss (1%) and two week needed 
for cultivation (Chiu et al., 2010). Rapid methods for prenatal diagnosis of fetal 
chromosomal aneuploidies have been developed. This method is multicolor fluorescence in 
situ hybridization (FISH). FISH is very reliable but requires intact cells and it can only be 
used on fresh samples (Klinger et al.,1992) The other method is quantitative fluorescent 
polymerase chain reaction  PCR anaylsis (real-time PCR) (Lo et al., 1997). Real-time PCR is a 
powerful tool for quantifying gene expression combining both high sensitivity and 
specificity with efficient signal detection (Kubista, 2008). A major advantage of real-time 
PCR is that it can be used to determine the amount of initial temlates (Heidi et al., 1996). In 
addition, by making use of a closed whereby the samples are analyzed directly in PCR 
reaction vessel during the amplification. Furthermore, the assay is less prone contamination  
(Zimmerman, 2006). Real-time PCR has found wide spread applicability in the analysis of 
gene expression measurement and cell-free nucleic acids in body fluids. The assay is readily 
amenable to automation, and by making use of the current real-time PCR 96-384 well 
formats. The discovery of cff DNA in maternal plasma in 1997 has opened non-invasive 
prenatal diagnosis (NIPD). This research area is a rapidly developing and dynamic field. 
NIPD using cell-free fetal DNA (and RNA) is likely to become increasingly available within 
the next few years. There have been a lot of reported applications, including fetal rhesus-D 
genotyping (Bombard et al.,2011), fetal sexing for X-linked disorders (Costa et al., 2002), 
paternally inherited genetic diseases, and pregnancy-associated conditions such as 
preeclampsia (Zhong et al., 2001). Diagnosing by using free DNA a variety of limitations 
due to some of the features of this resource. CffDNA analyses would be applicable only 
when the involved target sequence is in the fetus but absent from mother, such as paternally 
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inherited disorders or ろde novoわ mutations (Gonzales et al., 2005). In this chapter, we 
focused on NIPD with real-time PCR via the use of cell-free fetal DNA  
2. The cell free fetal DNA  
The cffDNA circulate  freely in the peripheral blood during pregnancy and  derived from 
the placenta, the fetal hematopoietic system, or the amniotic fluid, it appears to be 
transferred as a naked molecule or very quickly assumes that form (Robert et al., 2003). The 
cffDNA  is most likely of placental origin (Bianchi&Lo, 2001). It rapidly disappears from the 
maternal circulation folowing chilbirth. Unlike fetal cells, which can persist for decades, 
cffNA are rapidly cleared from the maternal circulation and are undetectable 2 hours after 
delivery. PHG foundation group was summarized of key properties of fetal/placental 
elements in maternal blood, specifically cell-free fetal nucleic acids and intact fetal cells 
(table 1). Fetal DNA molecules are amount to just 3–6 % of the total DNA circulating in the 
maternal plasma (Lo et.al., 1998a). High levels of cffDNA in maternal plasma is associated 
with several pregnancy related disorders (Holzgre et al., 2001). The size of cffDNA have 
confirmed that it is of average size 300 bp or smaller than maternal free DNA (Chan et al., 
2004). Fetal DNA can be detected in maternal plasma between the fifth to seventh week 
gestation  (Gonzalez et al., 2005). The technical problem that cffDNA makes up a low 
proportion in maternal plasma in high background of maternal DNA.  
 
Properties cffNA Fetal Cells 
Earliest detection 4 weeks ~ 7 weeks 
Proportion 5-10% 0.0001 - 0.01% 
 
Persistence in maternal 
blood 
< 24 hours > 27 years 
 
Relevant physical 
properties 
Short fragments Dense nucleus 
 
Table 1. Differences cell-free fetal nucleic acids and intact fetal cells (phg foundation, 2009) 
2.1 Isolation of cell fetal free DNA from maternal plasma 
The discovery of cffDNA in maternal plasma of pregnant women in 1997 by Lo et al (Lo et 
al., 1998b), many laboratories have shown that several protocols for isolating this material. 
The nucleic acid extraction procedure is most important for the detection of fetal nucleic 
acids in maternal plasma. To separate plasma from whole blood, parameters including 
multiple centrifugations at different speed, filtration to rmove contaminating intact or 
apoptotic cells, and removal of protein impurities have been explored (Jorgez et. al., 
2006).The critical point with techniques used is the avoidance of contamination from other 
blood components. The protocols for isolation of plasma were optimized to reduce cell lysis. 
The standard protocol for isolating plasma, which is commanly, involves two centrifugation 
steps. First step is high speed. This step is removal of cellular material from plasma layer. 
Store plasma samples in smaller aliquots (500 µL). The second step, different commercial 
kits have been used to isolate cell free fetal DNA. The free fetal DNA particles in maternal 
blood are promising as an important step for diagnosis of numerical and structural 
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chromosome anomalies belonging to fetus without invasive procedures. The main problem 
is that extremely low concentration of fetal DNA is present in maternal plasma. Circulating 
fetal DNA concentration increases with progression of pregnancy and disappears from 
maternal plasma rapidly after delivery , with median half-life of 16.3 min ( Lo et al., 1999, 
Smid et al., 2003). However, methods have been optimized for the extraction of fetal DNA 
from maternal plasma. Although extracted DNA is generally stable for long periods, levels 
of fetal DNA have been shown to decrease over long storage periods. Our laboratories use 
of the QIAampDSP virus kit (QIAGEN). To extract DNA,  600 µL of plasma from maternal 
sample for method.  
3. Clinical applications of real-time PCR for non-invasive prenatal diagnosis 
For many years, scientisist has focused seperation of fetal cells and fetal DNA in maternal 
blood. The discovery of circulating cell-free fetal nucleic acids in maternal plasma has 
opened up new possibilities for non invasive prenatal diagnosis. Cff DNA is detectable in 
maternal blood as early as 5-7 weeks of gestation (Honda et al., 2002; Galbiati et al., 2005). 
CffDNA present has been used succesfully for non-invasive diagnosis of the fetal sex and 
fetal Rhd genotype in Rh negative women (Chen et al., 2004). Recent advances in molecular 
methods enable other applications of fetal DNA purified from maternal plasma samples 
(Vlkova et al., 2010). Studies put more emphasis on this area (Purvosunu et al., 2008). The 
sensivity of the studies that have been recently carried out by the devoleped PCR techniques 
has been increased, but the greatest difficulty encountered is the isolation of pure and high 
scale fetal DNA. By doing this isolation, the need of invasive procedures, such as 
amniocentesis will largely be eliminated (Hahn et al., 2008).  
3.1 Fetal RHD status 
Hemolytic disease of newborn (HDN) is a clinic phenomenon, which occurs during 
pregnancy due to the RhD alloimmunization between  Rh (-) pregnant woman, who has 
become sensitive with RhD antigens, and  her Rh (+) fetus. Unnecessary application of Anti 
D Ig can be prevented for pregnant women who carry Rh – fetus, also this results in a better 
follow-up of pregnant women who carry Rh+ fetus with the detection of RhD genotype of 
fetus in maternal plasma at the first trimester of pregnancy. RHD was used as a test-bed to 
prove the effectiveness of detecting a paternally inherited allele carried bty circulating free 
fetal DNA in maternal plasma (Lo et al., 1997). Maternal plasma-based RHD genotyping has 
been succesfully implemented in our laboratories for use as a non-invasive prenatal 
diagnosis where alloimmunization has occured (Gunel et al., 2010). Real-time PCR has been 
the choice diagnostic test used. Fetal RhD detection can be applied routinely to Rh (-) 
women and the use of human anti –D can be significantly reduced (Hahn et al., 2008). A 
reduction in anti-D administration also has economic implications. Rh locus is composed of 
two homologous genes RHD and RHCE (97% homology) closely linked on chromosome 
1p34-p36. Each of these genes consists of 10 exones, and they contain 69 kb of DNA. The 
regions of exone 7 and exone 10 within the RhD gene are the areas of focus. In all positive 
results, the RhD blood group has also been found positive (Huang, 1998, Wagner and Flegel, 
2000). In a white population, D-negative individuals are homozygous for a deletion of RHD. 
The D-negative phenotype, absence of the whole RhD protein from red cell membrane. 
Different mechanisms may explain rare phenotypes, including gene conversion events 
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between homologous RHD and RHCE producing hybrid genes, nonsense mutations, and 
deletions or insertions interrupting the reading frame of the messenger RNA (Rouillac-Le 
Sciellour et al., 2004. Gunel et al., 2011).  
3.2 Fetal sexing 
Researchers had focused on the detection of fetal-derived paternally inherited DNA because 
Y chromosome of male fetus, which were absent in the genome of the pregnant women (Lo 
YMD, 2010). Most sex-linked disease are recessive X-linked disesae such as haemophilia and 
and Duchenne muscular dystrophy. To determine the sex of a fetus by real-time PCR using 
DYS14 and SRY genes on  and Y chromosome. The genotyping of these fetal loci helps 
preventing invasive procedures in the case of X-linked disorders (Rijinders et al., 2004). 
CffDNA technology has been used to identify babies at risk of congenital adrenal 
hyperplasia by identifying fetal sex at the requisite stage in pregnancy in 6-7 weeks 
(Rijinders et al., 2001). 
3.3 Determination of fetal aneuploidy by real-time PCR  
The free fetal DNA particles in maternal blood are promising as an important step for 
diagnosis of numerical and structural chromosome anomalies belonging to fetus without 
invasive procedures. The direct analysis of cff DNA for the NIPD of trisomies is mainly 
complicated. The most common chromosomal abnormalities in live births is trisomi 21 and 
other chromosomes 13, 18 trisomies has rapidly analysis with real-time PCR methods. The 
full fetal karyotype is usually determined using cultured cells and need two weeks for 
result. Real-time PCR has rapidly determination of template copy numbers. Tong et. al. had 
first demonstration of the direct detection of trisomi 18 from maternal serum (Tong et al., 
2006). They were achived with use of the epigenetic allelic ratio method. Enrich et.al., had 
used sequence-specific taq of known chromosomal location as a quantitative representation 
of individual chromosomes in maternal plasma. Trisomi 21 detection by massively parallel 
shotgun sequencing (MPSS) in high risk women is complicated. Their overall classification 
showed 100% sensitivity and 99.7% specificity of detection of fetal trisomi 21 (2011). Lo et 
al., described a novel method for the NIPD of Down syndrome. Candidate mRNA markers 
shoul be encoded from genes located on chromosome 21. The PLAC4 gene on chromosome 
21 and originating from fetal cells in the placenta and cleared following delivery of the fetus 
(Lo et al., 2007). If the fetus is euploid, that is containing two copies of the PLAC4 gene, 
because SNP (single nucleotide polymorphism) alleles would be 2:1. (Lo, 2009). The first 
large-scale noninvasive prenatal detection of trisomi 21 using multiplex sequencing to 
analyze fetal DNA from maternal plasma by Chiue et. al., (2011). They show that   100% 
sensitivity and 97.9% specificity of detection of fetal trisomi 21. They report a % 2.1 false-
positive rate. This method replace invasive procedures and would be eliminated unintended 
procedures fetal losses as well as better targeting of pregnancy-related interventions.  
3.4 Pre-eclampsia and cell free fetal nucleic acids 
Preeclampsia is a potentially dangerous disorder specific to the second half of pregnancy, 
affecting about 2.5–3% of women (Redman & Sargent, 2005). The etiology of this disease 
involves the placenta. Real-time PCR, it is now possible to measure DNA/RNA content 
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accuracy. The increased presence of cell-free fetal DNA indicates that preeclampsia is 
associated with damage to the placenta (Zhong et al., 2001) The cell-free fetal DNA levels in 
maternal blood in preeclamptic patients are significantly higher than those of normal 
pregnancies, and this elevation precedes the clinical occurrence of preeclampsia by 
approximately 1-2 weeks. The results of the studies in this area are important for pregnancy 
follow-up. The change of free fetal DNA levels in maternal blood in healthy pregnancies 
according to gestation week, was shown in various publications (Zhong et al.,2001, Ferina et 
al.,2004, Carty et al., 2008). By using real-time PCR technology was shown to be elevated ~ 
5-fold in samples obtained from pregnant women with preeclampsia when compared with 
an eual-sized cohort of normotensive, pregnant women ( Lo et al., 1999) All study subjects 
were pregnant women carrying male fetuses, and investigators amplified sequences from 
the SRY gene distinguish fetal from maternal DNA (Levine et al., 2004).  
4. Summary 
The discovery of cell-free fetal DNA (cffDNA) in maternal blood has exciting possibilities 
for non-invasive prenatal diagnosis (NIPD). Free fetal DNAs stemming from the destruction 
of fetal cells from seven weeks of gestation transport to the maternal blood via the bi-sidal 
flow through the placenta.The free fetal DNA particles in maternal blood are promising as 
an important step for diagnosis of numerical and structural chromosome anomalies 
belonging to fetus without invasive procedures. The detection and quantification of gene 
rearrangement, amplification, translocation or deletion is a significant problem, both in 
research and in a clinical diagnostic setting. Real-time PCR has become a well-established 
procedure for quantifying levels of gene expression. There are a number non-invasive 
prenatal diagnosis methods such as sex diagnosis or Rh blood type incompatibility and 
single-gene disorders have been reported. Different problems associated with placental 
growth and development result in changed levels of cffDNA. The cell-free fetal DNA levels 
in maternal blood in preeclamptic patients are significantly higher than those of normal 
pregnancies. It is possible the diagnostic utility of adding cffDNA concentration to the 
current panel of biomarkers. The test can be used very early of pregnancy, with no risk to 
the mother and child. 
5. References 
Bombard AT, Akolekar R, Farkas DH, VanAgtMael AL, Aquino F, Oeth P, Nicolaides K. 
(2011).  
Fetal RHD  genotype detection from circulating cell free- fetal DNA in maternal plasma in 
non-sensitized RhD negative women. Prenat. Diagn. 31, 802-808.  
Carty DM, Delles C, Dominiczak A. (2008). Novel Biomarkers for Predicting Preeclampsia. 
Trends Cardiovasc Med. 18, 186-194. 
Chan KC, Zhang  J, Hui AB, Wong N, Lau TK, Leung TN, Lo KW, Huans WS, Lo YM. 
(2004).Size Distributions of Maternal and Fetal DNA in Maternal Plasma. Clin 
Chem.50, 88-92. 
Chen JC, Lin TM, Chen YL, Wang YH, Jin YT, Yue CT.( 2004). RHD 1227A is an important 
genetic marker for RhD(el) individuals. Am J Clin Pathol,122, 193-198. 
Chiue RW,  Ranjit Akolekar R,  Zheng YWL, Leung TY,Sun H, Chan KCA, Lun FMF, Go TJI, 
Lau ET, William WK  Leung WC, Tang RYK, Yeung SKC, Lam H,  Kung YY,  
www.intechopen.com
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
168 
Zhang X,  Vugt JMG,  Minekawa R, Tang MHY,Wang J,  Oudejans CBM, Lau TK, 
Nicolaides KH, Y M Dennis LYM. (2011). Non-invasive prenatal assessment of 
trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity 
study. BMJ, doi:10.1136/bmj.c7401, 1-9. 
Costa JM, Benachi A, Gautier E. (2002). New strategy for prenatal diagnosis of X-linked 
disorders. N. Engl. J Med. 346, 1502. 
Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L,Tim R, Lu V, McCullough R, 
McCarthy   
E,Nygren A O.H, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V,  Oeth P, 
Cantor C.R, Bombard A and van den Boom D. (2011). Noninvasive detectiton of 
fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical 
setting. Am J Obstet Gynecol, 204:205.e1-11. 
Farina A, Sekizawa a, Rizzo N, Concu M, Banzola I, Carinci P, Simonazzi G, Okai T. (2004). 
Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly 
correlated to the time elapsed from the onset of preeclampsia to the collection of 
blood. Prenat Diagn, 2, 293–297. 
Galbiati S, Smid M, Gambini D, Ferrari A, Restagno G, Viora E, Campogrande M, Bastonero 
S, Pagliano M, Calza S. (2005). Fetal DNA detection in maternal plasma throughout 
gestation. Human Genet, 117, 243-248.  
Gonzales GC, Garcia HM, Trujillo TMJ, Lorda DI, Rodriquez AM, Infantes F, Gallego J, Diaz 
RJ, Ayusa C, Ramos C. (2005). Application of fetal DNA detection in maternal 
plasma: A prenatal diagnosis unit experience. Journal of Histochem and Cytochem. 53, 
307-314. 
Gunel T , Kalelioğlu I , Ermiş H , Aydınlı K. (2010). Detection of fetal RhD gene from 
maternal blood. J Turkish - German Gynecol Assoc, 11,82-85. 
Gunel T, Kalelioglu I, Gedikbasi A. Ermis, H, Aydinli K. (2011) Detection of fetal RHD 
pseudogene (RHDΨ) and hybrid RHD-CE-Ds from RHD-negative pregnant 
women with a free DNA fetal kit. Genet. Mol. Res. 10 (4), 2653 - 2657  
Hahn S, Chitty L. (2008) Noninvasive prenatal diagnosis: current practice and future 
perspectives. Current Opinion in Obstetrics and Gynecology, 3, 150-157. 
Heid CA, Stevans J, Livak KJ, Williams PM. (1996). Real-time quantitative PCR. Genome Res. 
6, 986-994. 
Holzgreve W, Li JC, Steinborn A, Kulz T, Sohn C, Hodel M, Hahn S. (2001). Elevation in 
erythroblast count in maternal blood before yhe onser of pre-eclapmsia. Am. 
J.Obstet.Gynecol. 184, 165-168. 
Honda H, Miharu N, Ohashi Y, Samura O, Kinutani M, Hara T, Ohama K. (2002). Fetal 
gender determination in early pregnancy through qualitative and quantitative 
analysis of fetal DNA in maternal serum. Hum Genet.110, 75.79. 
Jorgez CJ,  Dang DD,, Simpson JL, Lewis DE, Bischoff FZ. (2006). Quantity versus quality: 
optimal methods for cell-free DNA isolation from plasma of pregnant 
women.Genet in Med.10, 615-619. 
Klinger K, Landes G, Shook D.( 1992). Rapid detection of chromosome aneuploidies in 
uncultured amniocytes by using fluorescence in situ hybridization (FISH). 
Am.J.Hum.Genet. 51, 55-65.  
www.intechopen.com
 
Real-Time Quantitative PCR for Detection Cell Free Fetal DNA 
 
169 
Levine RJ, Qian C, LeShane ES, Yu KF, England LJ, Schisterman EF, Wataganara T, Romero 
R, Bianchi DW. Two-stage elevation of cell-free fetal DNA in maternal sera before 
onset of preeclampsia (2004). Am.J.Obst.Gyn.190, 707-713. 
Kubista M. Emerging real-time PCR application. (2008). Drug Dis. 
Lo YMD, Corbetta N, Chamberlian PF, Rai V, SargentIL, Redman CW. (1997). Presence of 
fetal DNA in maternal plasma and serum. Lancet,  350, 485-487. 
Lo YMD, Hjelm NM, Fidler C, Sargent IL, Murpy MF, Chamberlain PF, et.al. (1998a) 
Prenatal diagnosis of  fetal status by molecular analysis of maternal plasma.. N Engl 
J Med .339, 1734-1738.  
Lo YMD, Tenis MS, Lau MS, Haines CJ. (1998b). Quantitative analysis of fetal DNA in 
maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J 
Hum Genet 62, 768-75. 
Lo YMD, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, Haines CJ, Redman CW.(1999). 
Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin 
Chem.45, 184-188.  
Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, Heung MM, et al., (2007). Plasma placental 
RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. 
Nat Med. 13, 218-223. 
Lo YM. (2009). Noninvasive prenatal detection of fetal chromosomal aneuploidies by 
maternal plasma nucleic acid analysis: a review of current state of the art. BJOG. 
116, 152-157. 
Lo YMD. (2010). Noninvasive prenatal diagnosis 2020. Prenat Diagn, 30, 702-703. 
Lun FMF, Chiu RWK, Chan KCA, Leung TY, Lau TK, Lo YMD. (2008). Microfluidics digital 
PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin 
Chem. 54, 1664-1672.  
Phg foundation (2009). Making science work for health. www.phgfoundation.org. 
Purwosunu Y, Sekizawa A, Okai T. (2008), Detection and quantification of fetal DNA in 
maternal plasma by using LightCycler technology. Methods Mol Biol,  444, 231-238. 
Redman CW, Sargent IL. (2005). Latest advances in understanding preeclampsia. Science. 
308,1592–1594. 
Rijnders RJ, Christiaens GC, Bossers B, van der Smagt JJ, van der Schoot CE, Haas M.(2004), 
Clinical applications of cell free fetal DNA from maternal plasma. Obstet.Gynecol. 
103, 157-164.  
Rijnders, R.J.P. et al (2001). Fetal Sex Determination from Maternal Plasma in Pregnancies at 
Risk for Congenital Adrenal Hyperplasia. Obstet Gynecol 98, 374-378. 
Robert M. Angert, Erik S. LeShane, Y.M. Dennis Lo, Lisa Y.S. Chan, Laurent C. Delli-Bovi 
and Diana W. Bianchi. (2003). Fetal Cell-free Plasma DNA Concentrations in 
Maternal Blood Are Stable 24 Hours after Collection: Analysis of First- and Third-
Trimester Samples. Clinical Chemistry, 49, 195-198. 
Rouillac-Le Sciellour C, Puillandre P, Gillot R, Baulard C, Metral S, Le Van Kim C, Cartron 
JP, Colin Y, Brossard Y (2004)  Large-scale pre-diagnosis study of fetal RHD 
genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol. 
Diagn. 8(1): 23-31 
Tong YK, Ding C, Chiu RWK, Gerovassili A, Chim SSC, Leung TY, Leung TN, Lau TK, 
Nicolaides KH, Lo YMD. Noninvasive Prenatal Detection of Fetal Trisomy 18 by 
www.intechopen.com
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
170 
Epigenetic Allelic Ratio Analysis in Maternal Plasma: Theoretical and Empirical 
Considerations. Clin Chem. 52, 2194-2202.  
Vlkova B, Szemes T, Minarik K, Turna J, Celec P. Advances in the research of fetal DNA in 
maternal plasma for noninvasive prenatal diagnostics. (2010). Med Sci Monit, 16.4, 
85-91. 
Zhong XY, Holzgreve W, Hahn S.(2001), Circulatory fetal and maternal DNA in pregnancies 
at risk and those affected by preeclampsia. Ann.N.Y.Acad. Sci, 945,138-140. 
Zimmermann, B., El-Sheikhah, A., Nicolaides, K., Holzgreve, W. And Hahn, S. (2005). 
Optimized real-time quantitative PCR measurement of male fetal DNA in maternal 
plasma. Clin. Chem. 51, 1598–1604.  
Zimmermann B, Levett L, Holzgreve W, Hahn S. Use of real-time polymerase chain reaction 
for detection of fetal aneuploidies. (2006). Meth of Mol Biy , 336, 83-100. 
www.intechopen.com
Prenatal Diagnosis - Morphology Scan and Invasive Methods
Edited by Dr. Richard Choy
ISBN 978-953-51-0614-2
Hard cover, 210 pages
Publisher InTech
Published online 29, June, 2012
Published in print edition June, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides detailed and comprehensive coverage on various aspects of prenatal diagnosis-with
particular emphasis on sonographic and molecular diagnostic issues. It features sections dedicated to
fundamentals of clinical, ultrasound and genetics diagnosis of human diseases, as well as current and future
health strategies related to prenatal diagnosis. This book highlights the importance of utilizing fetal
ultrasound/clinical/genetics knowledge to promote and achieve optimal health in fetal medicine. It will be a very
useful resource to practitioners and scientists in fetal medicine.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Tuba Gunel, Hayri Ermis and Kilic Aydinli (2012). Real-Time Quantitative PCR for Detection Cell Free Fetal
DNA, Prenatal Diagnosis - Morphology Scan and Invasive Methods, Dr. Richard Choy (Ed.), ISBN: 978-953-
51-0614-2, InTech, Available from: http://www.intechopen.com/books/prenatal-diagnosis-morphology-scan-
and-invasive-methods/real-time-quantitative-pcr-for-detection-cell-free-fetal-dna
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
